FDA Approves Axatilamab for Chronic Graft-versus-Host Disease
Key Insights
The FDA has granted accelerated approval to Axatilamab (search) for chronic graft-versus-host disease (search) (GVHD (search)) in patients who have failed first-line treatments.
Axatilamab (search), a drug based on the research of Dr. Kelli MacDonald, works by suppressing harmful immune cells that cause chronic GVHD (search).
Clinical trials demonstrated that Axatilamab (search) significantly reduced symptoms in up to 75% of patients with chronic GVHD (search).
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Axatilamab (search) for the treatment of chronic graft-versus-host disease (search) (GVHD (search)) in adult and pediatric patients aged 12 years and older after failure of one or two prior lines of systemic therapy. This approval marks a significant advancement in the treatment of chronic GVHD, a major complication following stem cell transplants. The approval is based on research led by Dr. Kelli MacDonald at QIMR Berghofer (search) Medical Research Institute.
Mechanism of Action and Clinical Efficacy
Axatilamab (search) is designed to suppress harmful immune cells responsible for attacking the recipient's organs and tissues in chronic GVHD (search). This condition leads to inflammation and fibrosis, causing debilitating symptoms, particularly in the skin and lungs. Clinical trials published in the New England Journal of Medicine demonstrated that Axatilamab significantly reduced symptoms in up to 75% of patients who had failed to respond to initial steroid-based therapy.
Addressing an Unmet Need
Chronic GVHD (search) remains a significant challenge in blood cancer treatment, often leading to serious complications and death in patients undergoing stem cell transplants. Current treatments are often inadequate, leaving a substantial proportion of patients with unmet medical needs. Axatilamab (search) offers a new therapeutic avenue for these patients, providing hope for improved outcomes and quality of life.
Origin and Development
The development of Axatilamab (search) stems from Dr. MacDonald's breakthrough discovery in 2014 of an antibody that could prevent chronic GVHD (search). Her lab at QIMR Berghofer (search) identified the cellular process causing chronic GVHD and developed the antibody to block this process. This research has now translated into an FDA-approved treatment available to patients in the U.S.
Availability and Future Directions
Healthcare providers in the U.S. will soon have access to full prescribing information on the FDA's website. While the drug is now available in the U.S., its availability in Australia is yet to be determined. This approval represents a major step forward in transplant immunology and highlights the importance of persistent research in addressing clinical challenges.